| Treatment groups | FMS/RSV vs. FMS | FMS/RSV vs. RSV | ||||
---|---|---|---|---|---|---|---|
 | FMS/RSV (N = 46) | FMS (N = 45) | RSV (N = 44) | LSM difference (SE) | P-value | LSM difference (SE) | P-value |
siSBP | Â | Â | Â | Â | Â | Â | Â |
  Baseline | 152.52 (9.85) | 151.33 (8.99) | 154.72 (9.46) |  |  |  |  |
  Week 8 | 132.05 (17.45) | 134.63 (18.70) | 150.21 (17.19) |  |  |  |  |
  Change | −20.47 (15.60) | −16.70 (16.54) | −4.50 (15.50) |  |  |  |  |
   P-value | <0.001a | <0.001b | 0.061a |  |  |  |  |
 ANCOVA results |  |  |  |  |  |  |  |
  LSM (SE) | −21.89 (2.44) | −19.61 (2.66) | −6.86 (2.71) | −2.28 (3.37) |  | −15.03 (3.39) |  |
  (95% C.I.) | (−26.71, −17.07) | (−24.88, −14.35) | (−12.22, −1.50) | (−8.94, 4.39) | 0.500d | (−21.75, −8.31) | <0.001d |
siDBP | Â | Â | Â | Â | Â | Â | Â |
  Baseline | 89.42 (8.32) | 85.78 (9.30) | 93.08 (8.46) |  |  |  |  |
  Week 8 | 80.10 (10.47) | 79.58 (8.47) | 91.73 (11.46) |  |  |  |  |
  Change | −9.32 (11.23) | −6.20 (9.98) | −1.35 (9.18) |  |  |  |  |
   P-value | <0.001a | 0.001a | 0.335a |  |  |  |  |
 ANCOVA results |  |  |  |  |  |  |  |
  LSM (SE) | −10.13 (1.42) | −9.45 (1.59) | −1.18 (1.61) | −0.68 (1.98) |  | −8.95 (2.02) |  |
  (95% C.I.) | (−12.94, −7.31) | (−12.60, −6.30) | (−4.37, 2.01) | (−4.60, 3.25) | 0.734d | (−12.94, −4.95) | <0.001d |
LDL-C | Â | Â | Â | Â | Â | Â | Â |
  Baseline | 171.33 (36.02) | 164.09 (39.56) | 161.39 (26.71) |  |  |  |  |
  Week 8 | 81.46 (27.10) | 154.40 (52.37) | 77.25 (23.33) |  |  |  |  |
  Percentage change | −52.36 (12.97) | −6.52 (20.48) | −51.52 (15.80) |  |  |  |  |
   P-value | <0.001b | 0.112c | <0.001c |  |  |  |  |
 ANCOVA results |  |  |  |  |  |  |  |
 LSM (SE) | −52.74 (2.57) | −5.83 (2.77) | −50.92 (2.83) | −46.91 (3.53) |  | −1.82 (3.57) |  |
 (95% C.I.) | (−57.82, −47.66) | (−11.31, −0.35) | (−56.52, −45.31) | (−53.89, −39.92) | <0.001d | (−8.89, 5.24) | 0.611d |